Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the presentation of two posters, both addressing preclinical results with the company’s pan-caspase inhibitors, at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015.
Poster #1315, “Alcohol stimulates macrophage activation through caspase dependent, hepatocyte derived release of CD40L containing extracellular vesicles,” and poster #1522, “Emricasan, a pan caspase inhibitor, improves survival and portal hypertension in a murine model of long-term common bile-duct ligation,” will both be displayed in the Poster Hall on Level 1 of the Moscone West Convention Center in Poster Session III on Monday, November 16, from 8:00 a.m. to 5:30 p.m. PST, with authors available for discussion at the posters from 12:30 p.m. to 2:30 p.m. PST. The posters are available in the Data section of the Conatus website at www.conatuspharma.com.
A third Conatus abstract (#LB6), scheduled for a late-breaking oral presentation at 4:15 p.m. PST today, was one of 16 selected as key abstracts (from among the 2,299 abstracts accepted for presentation at The Liver Meeting®) and highlighted by Gyongy Szabo, M.D., Ph.D., in the AASLD President’s press conference on Saturday.
“We are excited to continue building upon our database of support for emricasan’s underlying mechanisms of action,” said Al Spada, Executive Vice President of Research and Development and Chief Scientific Officer of Conatus. “The data being presented today further our understanding of caspase inhibition’s multiple physiological effects, and give us the confidence to proceed directly with our recently announced registration strategy involving multiple parallel Phase 2b clinical trials, the EmricasaN, a Caspase inhibitOR, for Evaluation, or ENCORE trials.” (Original Source)
Shares of Conatus Pharmaceuticals opened today at $3.55 and are currently trading up at $3.57. CNAT has a 1-year high of $11.74 and a 1-year low of $3.37. The stock’s 50-day moving average is $4.07 and its 200-day moving average is $4.77.
On the ratings front, Conatus has been the subject of a number of recent research reports. In a report issued on November 5, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on CNAT, with a price target of $9, which implies an upside of 153.5% from current levels. Separately, on September 25, JMP’s Liisa Bayko maintained a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Stephen Willey and Liisa Bayko have a total average return of 25.7% and 27.0% respectively. Willey has a success rate of 56.0% and is ranked #43 out of 3842 analysts, while Bayko has a success rate of 54.1% and is ranked #170.
Overall, one research analyst has assigned a Hold rating and 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $10.75 which is 202.8% above where the stock opened today.
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.